The Institute for Clinical and Economic Review (ICER) has delivered a strong clinical and economic endorsement of today’s leading obesity drugs, while simultaneously warning that U.S. payers are unprepared for the scale of demand these therapies are likely to generate. In a final evidence report released Tuesday, ICER concluded that Novo Nordisk’s semaglutide (Wegovy, injectable … Read more
Zealand Pharma’s up-to-$2.5B collaboration with OTR Therapeutics highlights a strategic pivot in metabolic drug development.
Yarrow lands $1.37B China biotech deal, betting on first-in-class TSHR antibody for thyroid disease U.S.-based Yarrow Bioscience has secured its lead asset through a potential $1.37 billion licensing deal with China’s GenSci Pharmaceutical, picking up ex-China rights to a first-in-class antibody targeting autoimmune thyroid disease as it charts a broader expansion beyond its early platform … Read more
Sanofi has signed a global licensing agreement worth up to about $1.04 billion for an early-stage Alzheimer’s antibody targeting acetylated tau, marking the pharma’s second biotech deal of the day as it accelerates external pipeline building in neurology.
Dren Bio has expanded its strategic collaboration with Sanofi in a deal worth up to $1.8 billion, advancing next-generation B-cell depletion therapies and reinforcing deep-remission strategies in autoimmune disease.
Swedish orphan-drug specialist Sobi has agreed to acquire Arthrosi, a privately held biotech focused on next-generation gout therapies
The EU has finalized a sweeping Pharma Package deal, preserving eight years of data protection, adding new antibiotic incentives and giving member states new powers to secure medicine supply.
ICER released two notable updates this week: a final evidence report supporting cytisinicline’s role in smoking cessation and a draft review evaluating sibeprenlimab, atacicept and delayed-release budesonide for IgA nephropathy.
Teleflex is unloading its anaesthesia, urology and cardiac care businesses in a trio of deals worth more than $2B.
The UK has set the 2026 VPAG newer-medicine rebate at 14.5%, down sharply from 22.9% in 2025, reflecting slower NHS uptake and easing budget pressure. With an added 1% contribution, companies will pay 15.5% next year as talks begin to redesign the scheme for 2029 and beyond.